High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to see if increased doses of rituximab are safe and
effective for the initial treatment of indolent B-cell lymphomas. Rituximab (Rituxan) is a
type of drug called an "antibody" that specifically targets B-cell lymphoma cells, and is
approved by the FDA for the treatment of indolent B-cell non-hodgkin lymphomas and certain
other types of non-hodgkin lymphomas. Standard doses currently used may not be achieving
maximal efficacy. Higher doses have been shown to be safe in other clinical trials, and may
offer superior efficacy to the current standard dose. This trial also employs intermittent
maintenance doses of rituximab at the standard dose, which has been shown to prolong
remissions and survival in patients with relapsed indolent B-cell lymphomas. This trial is
designed to show that higher dose rituximab plus maintenance rituximab can achieve similarly
good results to chemotherapy approaches, but without chemotherapy-related toxicity.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Brigham and Women's Hospital Dana-Farber Cancer Institute Genentech, Inc.